Ramoplanin

Ramoplanin

Clinical data
Routes of administration	Oral
Legal status	US: ℞-only
Identifiers
CAS Number	76168-82-6
ATC code	None
PubChem	CID 16132338
UNII	0WX9996O2G
ChEMBL	CHEMBL1095892
Chemical data
Formula	C119H154ClN21O40
Molar mass	2554.07 g/mol
(what is this?)  (verify)

Ramoplanin (INN) is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.^[1]

Mechanism

It exerts its bacteriocidal effect by inhibiting cell wall biosynthesis, acting by inhibiting the transglycosylation step of peptidoglycan synthesis.^[2]

Uses

Its development has been fast-tracked by the U.S. Food and Drug Administration as a treatment for multiple antibiotic-resistant Clostridium difficile infection of the gastrointestinal tract,^[3] although it is unstable in the bloodstream, so can be taken only orally against such infections.^[4][5][6]

References

1. Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipeptide antibiotic. Annals of Pharmacotherapy. 2005 May;39(5):863-8. PMID 15784805
2. Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S. The mechanism of action of ramoplanin and enduracidin. Molecular Biosystems. 2006 Jan;2(1):69-76. PMID 16880924
3. Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Review of Anti Infective Therapy. 2006 Dec;4(6):939-45. PMID 17181409
4. Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. Journal of Drugs in Dermatology. 2007 Jan;6(1):97-103. PMID 17373167
5. Balagopal A, Sears CL. Clostridium difficile: new therapeutic options. Current Opinion in Pharmacology. 2007 Oct;7(5):455-8. PMID 17644040
6. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clinical Infectious Diseases. 2008 Jan 15;46 Suppl 1:S32-42. PMID 18177219